OPTIMIRA

Welcome to the Brand page for “OPTIMIRA”, which is offered here for Pharmaceutical and veterinary preparations and diagnostic agents, with a base of biologically active substances in the nature of proteins and nucleic acids, all for use in treating autoimmune and inflammation diseases, diseases of blood and lymphatic system, cancer, cardiovascular and circulatory diseases, diseases of the central nervous system, dental diseases, dermatology disorders, diseases of the digestive system, genetic diseases, infections, diseases of the kidney and genitourinary system, metabolic diseases, endocrinology diseases, musculoskeletal disorders, ophthalmology diseases, respiratory and pulmonary diseases, and gynecological diseases; medical diagnostic kits comprised of reagents and assays for testing of samples of a human or animal patient, tissue samples, biopsies, body fluids, smears, skin samples, mucosa samples and hair;optimization mira;chemicals used in industry and science, biologically active substances in the nature of proteins and nucleic acids, having affine and/or enzymatic properties, including enzymes and ribozymes; kits comprised of chemical reagents and assays for use in molecular-biological research;consultancy and contract research in the field of molecular biology, with regard to the development and optimization of biologically active substances; custom development of biochemical assay systems on a molecular-biological basis, in particular for research, medicine and environmental analytics; scientific research and development in the field of biologically active substances by means of evolutive biotechnology;.

Its status is currently believed to be active. Its class is unavailable. “OPTIMIRA” is believed to be currently owned by “BAYER SCHERING PHARMA AKTIENGESELLSCHAFT”.